Ectokinases as novel cancer markers and drug targets in cancer therapy


Loading...

Date

2015-03

Publication Type

Journal Article

ETH Bibliography

yes

Citations

Altmetric

Data

Abstract

While small‐molecule kinase inhibitors became the most prominent anticancer drugs, novel combinatorial strategies need to be developed as the fight against cancer is not yet won. We review emerging literature showing that the release of several ectokinases is significantly upregulated in body fluids from cancer patients and that they leave behind their unique signatures on extracellular matrix (ECM) proteins. Our analysis of proteomic data reveals that fibronectin is heavily phosphorylated in cancer tissues particularly within its growth factor binding sites and on domains that regulate fibrillogenesis. We are thus making the case that cancer is not only a disease of cells but also of the ECM. Targeting extracellular kinases or the extracellular signatures they leave behind might thus create novel opportunities in cancer diagnosis as well as new avenues to interfere with cancer progression and malignancy.

Publication status

published

Editor

Book title

Volume

4 (3)

Pages / Article No.

404 - 414

Publisher

Wiley

Event

Edition / version

Methods

Software

Geographic location

Date collected

Date created

Subject

Cancer marker; Drug design; Ectokinases; Exokinases; Extracellular matrix; Extracellular phosphorylation; Extracellular protein kinase; Personalized medicine

Organisational unit

03640 - Vogel, Viola (emeritus) / Vogel, Viola (emeritus) check_circle

Notes

Funding

Related publications and datasets